

21 February 2022

PLUS Statement on Ruling from the Romanian Competition Council

The Platform of Plasma Protein Users (PLUS) has learnt that the Romanian Competition Council (RCC) released a [statement](#) on February 15th 2022 stating: its finding of market strategy coordination between five named companies (Octapharma, Baxalta, CSL Behring, Biotest and Kedrion) between 2016-2018; its finding that the Plasma Proteins Therapeutic Association (PPTA) facilitated these practices; and its decision to levy fines in the amount of €71 million against them.

PLUS has learnt that the PPTA issued a response [statement](#) on February 16th stating their disagreement with the RCC ruling, outlining its grounds, and stating that it may choose to appeal.

For PLUS the priority is to ensure a stable and optimal access to immunoglobulins and other plasma derived medicinal products (PDMPs) which are vital life-saving treatments for a range of rare plasma related disorders.

PLUS is deeply concerned by the situation in Romania where supply tensions (particularly on immunoglobulins) are ongoing and have been further exacerbated by the COVID-19 pandemic. We are gravely concerned by any actions which could adversely affect the supply of these medications to patients thereby potentially endangering their health or even their lives and we strongly call for a response from the named companies to the relevant patient community.

PLUS will continue to closely monitor these developments and stands in full support of its Romanian patient communities, who require their access to such life-saving treatments to be at optimal treatment levels, and stable and reliable availability.

About PLUS

The Platform of Plasma Protein Users (PLUS) is a consortium of seven patient organisations representing people living with treatable rare plasma related disorders such as haemophilia, primary immunodeficiencies and alpha1 anti-trypsin deficiency among others. Together, these organisations represent the views of more than 110,000 people living with treatable rare plasma related disorders in Europe.

PLUS represent organisations of patients with treatable rare diseases linked by common therapies based on products manufactured from human plasma. For more information visit: <https://plasmausers.org/>